QT
ADAP

Quantbot Technologies’s Adaptimmune Therapeutics ADAP Stock Holding History

Quantbot Technologies’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2,000
Closed -$3K – 1542
2022
Q2 		$3K Hold
2,000
– – ﹤0.01% 1600
2022
Q1 		$4K Buy
+2,000
New +$5.4K ﹤0.01% 1544
2018
Q4 		– Sell
-8,036
Closed -$108K – 994
2018
Q3 		$108K Sell
8,036
-2,153
-21% -$22.6K 0.01% 861
2018
Q2 		$120K Buy
+10,189
New +$127K 0.01% 841

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Quantbot Technologies's ADAP Position: Q3 2022 in Review

Quantbot Technologies sold out of Adaptimmune Therapeutics (ADAP) in Q3 2022, closing a stake of 2,000 shares — an estimated $3K sold.

Quantbot Technologies first reported a position in ADAP in Q2 2018 and held it in 4 quarters. The position peaked at $120K in Q2 2018. 68 funds tracked by Wall St. Rank hold ADAP as of Q3 2022.

  • Quantbot Technologies reported no remaining Adaptimmune Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Quantbot Technologies sold 2,000 Adaptimmune Therapeutics shares in Q3 2022, an estimated $3K.
  • Quantbot Technologies first reported a position in Adaptimmune Therapeutics in Q2 2018 and held it in 4 quarters.
  • Quantbot Technologies's Adaptimmune Therapeutics position peaked at $120K in Q2 2018.
  • 68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2022.

Based on Quantbot Technologies's 13F filing for Q3 2022, filed 7 Nov 2022.